Giovanni Brandi

机构：Azienda USL di Bologna, University of Bologna · ORCID：0000-0003-0013-2858

发表论文 497 篇 · 总被引 18225 次 · h-index 67

代表论文

• FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions (2024 · Nature Reviews Clinical Oncology · 被引 194)
• Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges (2024 · International Journal of Molecular Sciences · 被引 36)
• Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study (2024 · Targeted Oncology · 被引 28)
• Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications (2024 · Cancers · 被引 17)
• A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study (2024 · BMC Cancer · 被引 17)
• The trend toward more target therapy in pancreatic ductal adenocarcinoma (2024 · Expert Review of Anticancer Therapy · 被引 16)